

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM762184

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	TRADEMARK SECURITY AGREEMENT		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
INSMED INCORPORATED		10/19/2022	Corporation: VIRGINIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	BIOPHARMA CREDIT PLC		
<b>Street Address:</b>	C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD		
<b>City:</b>	EXETER EX4 4EP		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Entity Type:</b>	Private Limited Company: ENGLAND AND WALES		
<b>PROPERTY NUMBERS Total: 18</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5723276	ARIKARES	
<b>Registration Number:</b>	5166666	ARIKAYCE	
<b>Registration Number:</b>	4575732	DEIMMUNIZED BY DESIGN	
<b>Registration Number:</b>	4575733	ENGINEERING IMMUNOTOLERANCE	
<b>Registration Number:</b>	5223468	INSMED	
<b>Registration Number:</b>	5692970	INSMED	
<b>Registration Number:</b>	5693071		
<b>Registration Number:</b>	6449851	NTM ACTION	
<b>Registration Number:</b>	6322594	NTM DIALOGUE	
<b>Registration Number:</b>	4575730	S	
<b>Registration Number:</b>	4588125	STEALTH BIOLOGICS	
<b>Registration Number:</b>	5981467	VOICES OF NTM LUNG DISEASE	
<b>Serial Number:</b>	90541522	ENSODEPPI	
<b>Serial Number:</b>	97241454	INSMED	
<b>Serial Number:</b>	97248207	INSMED	
<b>Serial Number:</b>	97392707	NCFBE DIALOGUE	
<b>Serial Number:</b>	97081865	PULMOVANCE	
<b>Serial Number:</b>	90541512	YUVIPTA	
<b>CORRESPONDENCE DATA</b>			

CH \$465.00 5723276

**Fax Number:** 2028874288

**Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.**

**Phone:** 2028874000

**Email:** mbeyene@akingump.com, DC\_IPDocketing@AKINGUMP.com

**Correspondent Name:** Mussie B Beyene

**Address Line 1:** 2001 K Street N.W.

**Address Line 4:** Washington DC, D.C. 20006

**ATTORNEY DOCKET NUMBER:** 687747.0066

**NAME OF SUBMITTER:** Mussie B Beyene

**SIGNATURE:** /Mussie B Beyene/

**DATE SIGNED:** 10/19/2022

**Total Attachments: 21**

source=Project Icon - Trademark Security Agreement (Executed)#page1.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page2.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page3.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page4.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page5.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page6.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page7.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page8.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page9.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page10.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page11.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page12.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page13.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page14.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page15.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page16.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page17.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page18.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page19.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page20.tif  
source=Project Icon - Trademark Security Agreement (Executed)#page21.tif

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT, dated as of October 19, 2022, is made by INSMED INCORPORATED (“Grantor”), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, the “Collateral Agent”) on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of October 19, 2022 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), by and among INSMED INCORPORATED., a Virginia corporation (“Borrower”), the other parties thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, as Collateral Agent, BPCR LIMITED PARTNERSHIP, (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of October 19, 2022 in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Trademark Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the “Trademark Collateral”):

(a) all of its Trademarks and all IP Licenses and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1 hereto, but excluding any “intent-to-use” application for registration of a United States Trademark for which a “Statement of Use” pursuant to Section 1(d) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) has not been filed with and accepted by the Applicable IP Office (but only excluding such intent-to-use application until such statement of use or amendment to allege use (as applicable) is filed with and accepted by the Applicable IP Office);

(b) all renewals and extensions of the foregoing;

(c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Trademarks and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Trademark Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN TRADEMARK COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.

THE TERMS OF SECTION 10 OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.

Section 7. Termination. Upon the absolute, unconditional and irrevocable payment in full of the Secured Obligations in accordance with the provisions of the Loan Agreement and the expiration or termination of the Term Loan Commitments, the security interest in the Trademark Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and all rights to the Trademark Collateral shall automatically revert to Grantors or any other Person entitled thereto. At such time, the Collateral Agent authorizes the filing by such Grantor of an appropriate termination hereof.

Section 8. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the security interest granted pursuant to this Trademark Security Agreement, the terms of this Trademark Security Agreement and the exercise of any right or remedy hereunder are subject to the provisions of the Intercreditor Agreement, dated as of October 19, 2022, by and between the Collateral Agent and OrbiMed Royalty & Credit Opportunities IV, LP and acknowledged and agreed to by Borrower (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time).

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

INSMED INCORPORATED

as Grantor DocuSigned by:

By:



Name: Sara Bonstein


Title: Chief Financial Officer

ACCEPTED AND AGREED  
as of the date first above written:

BIOPHARMA CREDIT PLC,  
as Collateral Agent

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By:   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member





*Signature Page to Trademark Security Agreement*






**TRADEMARK**  
**REEL: 007872 FRAME: 0775**

SCHEDULE I  
TO  
TRADEMARK SECURITY AGREEMENT


Trademark Registrations





REGISTERED TRADEMARKS OF INSMED INCORPORATED


MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
ARIKARES	United States Registration No. 5,723,276	Class 44, 45	Filed 12/22/17; Registered 4/9/19
ARIKAYCE	United States Registration No. 5,166,666	Class 5	Filed 6/28/13; Registered 3/21/17
DEIMMUNIZED BY DESIGN	United States Registration No. 4,575,732	Class 42	Filed 1/2/2014; Registered 7/29/14
ENGINEERING IMMUNOTOLERANCE	United States Registration No. 4,575,733	Class 42	Filed 1/2/2014; Registered 7/29/14
ENSODEPPI	United States Application No. 90/541,522	Class 5	Filed 2/23/21
INSMED	United States Registration No. 5,223,468	Class 5	Filed 10/28/13 ; Registered 6/13/17
INSMED	United States Registration No. 5,692,970	Class 5	Filed 11/30/17; Registered 3/5/19
INSMED	United States Application No. 97/241454	Class 5	Filed 1/27/22 (intent-to-use)
INSMED	United States Application No. 97/248207	Class 5	Filed 2/1/22 (intent-to-use); Application published 8/30/22
Lungs Design (New) 	United States Registration No. 5,693,071	Class 5	Filed 12/15/17; Registered 3/5/19; First use date: 12/12/18
NCFBE DIALOGUE & Lungs Design 	United States Application No. 97/392707	Class 41	Filed 5/3/22 (intent-to-use)
NTM ACTION & Design 	United States Registration No. 6449851	Class 41, 44	Filed 4/17/20; Registered 8/10/21
NTM DIALOGUE & Design 	United States Registration No. 6322594	Class 35, 41	Filed 5/8/18 (intent-to-use); Registered 4/13/21
PULMOVANCE	United States Application No. 97/081865	Class 10	Filed 10/19/21 (intent-to-use); Published 8/30/22
S (and design)	United States Registration No. 4575730	Class 42	Filed 1/2/2014; Registered 7/29/14


MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
			
STEALTH BIOLOGICS	United States Registration No. 4,588,125	Class 42	Filed 1/2/2014; Registered 8/19/14
VOICES OF NTM LUNG DISEASE & design 	United States Registration No. 5,981,467	Class 41	Filed 6/10/19 (intent-to-use); First Use: June 2019; Registered 2/11/20
YUVIPTA	United States Application No. 90/541,512	Class 5	Filed 2/23/21
AEROKAYCE	Argentina Application No. 3707987	Class 5	Filed 5/10/18 (claiming 11/10/17 priority date); Registered 9/17/20
ARIKAYCE	Argentina Registration No. 2709607	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 2/9/15
ARIKAYCE and Lungs Design 	Argentina Application No. 4022987	Class 5	Filed 6/15/21; Published 8/11/21
ARYKAYCE	Argentina Registration No. 2714357	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 3/18/15
ENSODEPPI	Argentina Application No. 4044210	Class 5	Filed 8/19/21 (includes 2/23/21 claim of priority of US app)
INSMED	Argentina Registration No. 702779	Class 5	Filed 1/8/14; Registered 12/30/14
 Lungs Design (New)	Argentina Registration No. 3109972	Class 5	Filed 5/23/18; Registered 9/10/20
 Lungs Design	Argentina Registration No. 2801728	Class 5	Filed 5/4/15 (based on US App. No. 86/444,498); Registered 5/10/16











MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
RIKACIA	Argentina Registration No. 2714358	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 3/18/15
SOLIKAYCE	Argentina Registration No. 3022183	Class 5	Filed 5/10/18 (claiming 11/10/17 priority date); Registered 9/23/19
YUVIPTA	Argentina Application No. 4044211	Class 5	Filed 8/19/21 (includes 2/23/21 claim of priority of US app); Published 10/13/21
ARAKAYCE	Australia Registration No. 2196561	Class 5	Filed 7/22/21; Registered 3/2/22
ARICASE	Australia Registration No. 2196560	Class 5	Filed 7/22/21; Registered 3/2/22
ARIKACE	Australia (via Madrid Protocol) IR Reg. No. 919298 Australian National Reg. No. 1175452	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 12/20/07
ARIKAYCE	Australia Registration No. 1947513	Class 5	Filed 8/9/18; Registered 8/9/18
ARIKAYCE	Australia (via Madrid Protocol) IR Reg. No. 1193205 Australian National Reg. No. 1608509	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 6/19/14
ENSOPEPPI	Australia (via Madrid Protocol) IR Reg. No. 1623021 Australian Trademark Reg. No. 2223711	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 1/1/22
INSMED	Australia Registration No. 1596331	Class 5	Transformation filed 1/25/19; Retains 11/13/13 Filing Date and Registration Date from IR. 1184673
INSMED	Australia (via Madrid Protocol) IR Reg. No. 1205306 Australian National Reg. No. 1627975	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86/103,118); Statement of Grant of Protection issued 11/6/14
INSMED	Australia (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	Australia (via Madrid Protocol) IR Reg. No. 1418071 Australian National Reg. No. 1948849	Class 5	Registered effective 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 4/4/19
PULMOVANCE	Australia IR Reg. No. 1405839 Australian National Reg. No. 1933832	Class 5, 10 ,44	Registered 2/28/18 Statement of Grant of Protection issued 4/18/19
PULMOVANCE	Australia Application No. 2298281	Class 5, 10	Filed 9/5/22


MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
YUVIPTA	Australia (via Madrid Protocol) IR Reg. No. 1636763 Australian Trademark Reg. No. 2239802	Class 5	Filed 8/18/21; Statement of Grant of Protection issued 3/22/22
AEROKAYCE	Brazil Registration No. 914644157	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 5/21/19
ARIKACE	Brazil Registration No. 840123612	Class 5	Filed 5/11/12; Registered 6/23/15
ARIKAYCE	Brazil Registration No. 840753381	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 10/4/16
ARIKAYCE & Lungs Design 	Brazil Application No. 924305312	Class 5	Filed 9/16/21; Published 10/13/21
ARYKAYCE	Brazil Registration No. 840753365	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 10/4/16
ENSODEPPI	Brazil (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Published 1/25/22
INSMED	Brazil Registration No. 840758324	Class 5	Filed 1/7/14 Registered 10/4/16
INSMED	Brazil (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
INSMED & Design 	Brazil Application No. 924305258	Class 5	Filed 9/16/21 Published 10/13/21
Lungs Design (New)  Lungs design (New)	Brazil Registration No. 914754203	Class 5	Filed 5/25/18 Registered 5/21/19
 Lungs Design	Brazil Registration No. 909328366	Class 5	Filed 5/4/15 (based on US App. No. 86444498) Registered 10/10/17
KAYSPIRIS	Brazil Registration No. 914644220	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date) Registered 5/21/19
PULMOVANCE	Brazil Registration No. 914249495	Class 5	Registered 2/28/18 (claiming

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
			8/31/17 priority date) Registered 4/2/19
PULMOVANCE	Brazil Registration No. 914249525	Class 10	Registered 4/2/19
PULMOVANCE	Brazil Registration No. 914249541	Class 44	Registered 4/2/19
SOLIKAYCE	Brazil Registration No. 914644246	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date) Registered 5/21/19
VONCERA	Brazil Registration No. 840131356	Class 5	Filed 5/18/12; Registered 6/23/15
YUVIPTA	Brazil (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Published 2/22/22
AEROKAYCE	Canada Registration No. 1076360	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 4/3/20
ARIKAYCE	Canada Registration No. 1083493	Class 5	Filed 5/1/18; Registered 10/5/20
ARIKAYCE	Canada Registration No. 1028519	Class 5	Filed 12/27/13 (claiming 6/28/13 priority date); Registered 6/19/19
ENSODEPPI	Canada (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Canada Registration No. TMA 1,030,256	Wares: pharmaceutical preparations for the treatment of infectious diseases	Registered 6/21/19
INSMED	Canada Registration No. TMA 1,030,296	Wares: Pharmaceutical preparations for the treatment of pulmonary diseases	Registered 6/21/19
INSMED	Canada (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	Canada Registration No. TMA110910	Class 5	Filed 5/23/18; Registered 10/6/21
KAYSPIRIS	Canada Registration No. TMA1095840	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 3/16/21
PULMOVANCE	Canada Registration No. TMA1082153	Class 5, 10, 44	Filed 2/28/18 (claiming 8/31/17 priority date); Registered 9/29/20

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
SOLIKAYCE	Canada Registration No. TMA1,084,282	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 10/8/20
YUVIPTA	Canada (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	China (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07
ARIKAYCE	China (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date)
ARIKAYCE	China Registration No. 32026395	Class 5	Filed 7/4/18; Registered 3/28/19
ARIKAYCE	China Application No. 63549280	Goods: Pharmaceutical preparations; pharmaceutical preparations for the treatment of lung infections and pulmonary diseases.	Filed 3/25/22
ENSODEPPI	China (via Madrid Protocol) IR Reg. No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 5/17/22
INSMED	China Registration No. 36237539	Class 5	Filed 1/25/19; Registered 9/28/19
INSMED	China (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86/103,118); Statement of Grant of Protection issued 2/5/15
INSMED	China App. No. 65911897	Class 5	Filed 7/12/22
INSMED	China (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	China (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 12/27/18
PULMOVANCE	China (via Madrid Protocol) IR Reg. No. 1405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 11/12/18
YUVIPTA	China (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 6/15/22
ARIKACE	European Union (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued


MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
			4/24/08
ARIKAYCE	European Union (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 1/22/15
ARIKAYCE	European Union Registration No. 018178392	Class 5	Filed 1/8/20; Registered 5/22/20
	European Union Registration No. 017898230	Class 35, 41	Registered 9/19/18
ENSOPEPPI	European Union (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 3/16/22
INSMED	European Union Registration No. 018014385	Class 5	Registered 4/24/19
INSMED	European Union (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86/103,118)  Statement of Grant of Protection issued 4/30/15
INSMED	European Unio (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	European Union (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date) Statement of Grant of Protection issued 1/18/19
	European Union Registration No. 017898231	Class 35, 41	Registered 9/19/18
NTM	European Union Registration No. 15538267	Class 35, 41	Filed 6/14/16; Registered 11/10/16
NTM ACTION & Design 	European Union Registration No. 018318263	Class 41, 44	Filed 10/7/20; Claim of priority from US app 88/876,082; Registered 3/9/2021
	European Union Registration No. 017975780	Class 35, 41	Filed 10/30/18 (claiming U.S. priority date); Registered 3/23/19
	European Union Registration No. 017898232	Class 35, 41	Registered 9/19/18




MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
PULMOVANCE	European Union (via Madrid Protocol) IR Reg. No. 1405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 11/13/18
YUVIPTA	European Union (via Madrid Protocol) IR Reg. No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 5/20/22
NTM IM DIALOG	Germany Registration No. 30 2016 017 991	Class 35, 41	Filed 6/21/16; Registered 8/20/16
INSMED	Hong Kong Registration No. 305519809	Class 5, 10	Filed 1/28/21; Registered 9/20/21
Lungs Design (New) 	Hong Kong Registration No. 305519818	Class 5, 10	Filed 1/28/21; Registered 6/11/21
ARIKAYCE	India (via Madrid Protocol) IR Reg. No. 1193205 (This IR has been accorded Indian National Reg. No. 2715355)	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 10/11/18
ENSODEPPI	India (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	India Registration No. 4070632 (Transformation of IR Reg. No. 1184673)	Class 5	Registered 7/22/19
INSMED	India (via Madrid Protocol) IR Reg. No. 1205306 (This IR has been accorded Indian National Reg. No. 2759312)	Class 5	Registered 4/28/14 (claiming 10/28/13 priority date); Statement of Grant of Protection issued 12/13/18
INSMED	India (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	India (via Madrid Protocol) IR Reg. No. 1418071 (This IR has been accorded Indian National Reg. No. 3924911)	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 3/11/19
PULMOVANCE	India (via Madrid Protocol) IR Reg. No. 1405839 (This IR has been accorded Indian National Reg. No. 3856988)	Class 5, 10, 44	Registered 2/28/18; (claiming 8/31/17 priority date); Statement of Grant of Protection issued 1/12/19
VONCERA	India Registration No. 2320391	Class 5	Filed 4/23/12; Registered 9/22/14
YUVIPTA	India (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	International Register Registration No. 919298	Class 5	Registered 3/9/07 (claiming 1/31/07 priority date); <i>Designated Jurisdictions:</i>



MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
			<i>Australia, China, the European Union, Japan, Macedonia, Norway, Russian Federation, Serbia, South Korea, and Switzerland</i>
ARIKAYCE	International Register Registration No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date) <i>Designated Jurisdictions: Australia, China, the European Union, India, Japan, Mexico, Norway, Russian Federation, South Korea, Switzerland, Israel</i>
ENSODEPPI	International Register Registration No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Registered 8/18/21; <i>Designated Jurisdictions: Australia, Brazil, Canada, China, European Union, India, Israel, Japan, Mexico, Norway, Philippines, Russia, Singapore, South Korea, Switzerland, and the United Kingdom</i>
INSMED	International Register Registration No. 1205306	Class 5	Filed 4/28/14 (claiming 10/28/13 priority date); <i>Designated Jurisdictions: Australia, China, the European Union, India, Japan, Norway, Russian Federation, South Korea, Switzerland, Israel</i>
INSMED	International Register Registration No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications); Registration issued 9/8/22; <i>Designated Jurisdictions: Australia, Brazil, Canada, China, European Union, India, Israel, Japan, Mexico, Norway, Philippines, Russia, Singapore, South Korea, Switzerland, and the United Kingdom</i>
Lungs Design (New) 	International Register Registration No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); <i>Designated Jurisdictions: Australia, China, the European Union, India, Japan, Mexico, Norway, Russian Federation, South Korea, and Switzerland</i>
PULMOVANCE	International Register Registration No. 1405839	Class 5, 10, 44	Registered 2/28/18 (claiming 8/31/17 priority date) <i>Designated Jurisdictions: Australia, China, EU, India, Japan, Mexico, Norway, South Korea, Switzerland, Israel</i>



MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
YUVIPTA	International Register Registration No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app) Registration issued 12/30/21  <i>Designated Jurisdictions: Australia, Brazil, Canada, China, European Union, India, Israel, Japan, Mexico, Norway, Philippines, Russia, Singapore, South Korea, Switzerland, and the United Kingdom</i>
ARIKAYCE	Israel (via Madrid Protocol) IR Reg No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date)
ENSODEPPI	Israel (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Israel (via Madrid Protocol) IR Reg No. 1205306	Class 5	Registered 4/28/14 (claiming 10/28/13 priority date)
INSMED	Israel (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
PULMOVANCE	Israel (via Madrid Protocol) IR Reg No. 1405839	Class 5, 10, 44	Registered 2/28/18; (claiming 8/31/17 priority date)
YUVIPTA	Israel (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	Japan (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 3/6/08
ARIKAYCE	Japan Registration No. 6153076	Class 5	Filed 7/17/18; Registered 6/14/19
アリケース ARIKAYCE in Katakana Characters - Version 1	Japan Registration No. 6152167	Class 5	Filed 10/4/18; Registered 6/14/19
アリケイス ARIKAYCE in Katakana Characters - Version 2	Japan Registration No. 6152168	Class 5	Filed 10/4/18; Registered 6/14/19
ARIKAYCE	Japan (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 12/4/14
ENSODEPPI	Japan (via Madrid Protocol) IR Reg. No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 7/21/22
ENSODEPPI in Katakana characters (Version 1)	Japan Registration No. 6472575	Class 5	Filed 2/24/21; Registered 11/17/21












MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
インソデッピ°			
ENSOPEPPI in Katakana characters (Version 2) エヌソデッピ°	Japan Registration No. 6472576	Class 5	Filed 2/24/21; Registered 11/17/21
INSMED	Japan Registration No. 6143968 (Transformation from IR Reg. No. 1184673)	Class 5	Filed 1/25/19 (retains 5/13/13 priority date from transformed IR Reg. No. 1184673) ; Registered 5/17/19
INSMED	Japan Registration No. 6266323	Class 5	Registered 7/6/20
INSMED	Japan IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86103118); Statement of Grant of Protection issued 12/4/14
INSMED	Japan (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
インスメッド INSMED in Katakana Characters	Japan Registration No. 6152169	Class 5	Filed 10/4/18; Registered 6/14/19
Lungs Design (New) 	Japan IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 8/18/19
PULMOVANCE	Japan (via Madrid Protocol) IR Reg. No. 405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 3/7/19
YUVIPTA	Japan (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
YUVIPTA in Katakana characters ユビプタ	Japan Registration No. 6472574	Class 5	Filed 2/24/21; Registered 11/17/21
ARIKACE	Macedonia (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 6/7/12
ARIKAYCE	Mexico (via Madrid Protocol) IR Reg. No. 1193205 (This IR has been accorded National Reg. No. 1489893)	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 2/26/15
ENSOPEPPI	Mexico (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Mexico (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
Lungs design (New) 	Mexico Application No. 2735448	Class 5	Filed 4/28/22
PULMOVANCE	Mexico Registration No. 2322436	Class 5	Filed 8/13/21; Registered 11/9/21
PULMOVANCE	Mexico Registration No. 2322437	Class 10	Filed 8/13/21; Registered 11/9/21
PULMOVANCE	Mexico Registration No. 2322405	Class 44	Filed 8/13/21; Registered 11/9/21
YUVIPTA	Mexico (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	Norway (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 2/1/13
ARIKAYCE	Norway (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 10/16/14
ARIKAYCE and Lungs Design (new) 	Norway Registration No. 308097	Class 5	Filed 10/16/19; Registered 1/31/20
ENSODEPPI	Norway (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Application published 6/13/22
INSMED	Norway (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86103118); Statement of Grant of Protection issued 2/12/15
INSMED	Norway (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	Norway (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 8/2/19
PULMOVANCE	Norway (via Madrid Protocol) IR Reg. No. 1405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 5/24/19
YUVIPTA	Norway (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ENSODEPPI	Philippines (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Philippines (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
YUVIPTA	Philippines (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	Russian Federation (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 3/20/13
ARIKAYCE	Russian Federation Registration No. 699115	Class 5	Filed 7/16/18 Registered 2/18/19
ARIKAYCE	Russian Federation (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date) Statement of Grant of Protection issued 2/19/15
ARIKAYCE and Lungs Design (new)  <b>ARIKAYCE</b>	Russian Federation Application No. 2022710673	Class 5	Filed 2/18/22 Registered 7/7/22
ENSODEPPI	Russian Federation (via Madrid Protocol) IR Registration No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app) Statement of Grant of Protection issued 1/25/22
INSMED	Russian Federation (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86103118) Statement of Grant of Protection issued 6/18/15
INSMED	Russian Federation (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	Russian Federation (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 2/7/19
YUVIPTA	Russian Federation (via Madrid Protocol) IR Registration No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 4/22/22
ARIKACE	Serbia (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 6/7/12
ENSODEPPI	Singapore (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Singapore (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
YUVIPTA	Singapore (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Published 4/1/22

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
AEROKAYCE	South Africa Application No. 2018/12688	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 7/29/22
ARIKACE	South Africa Registration No. 2012/10959	Class 5	Filed 4/26/12; Registered 1/6/14
ARIKAYCE	South Africa Registration No. 2014/00184	Class 5	Filed 1/6/14 (claiming 6/28/13 priority date); Registered 7/15/16
ARYKAYCE	South Africa Registration No. 2014/00185	Class 5	Filed 1/6/14 (claiming 6/28/13 priority date); Registered 11/27/15
INSMED	South Africa Registration No. 2014/10808	Class 5	Filed 4/29/14 (on the basis of intended use and the priority of US App. No. 86/103,118); Registered 3/30/18
INSMED	South Africa Registration No. 2013/31724	Class 5	Filed 11/13/13; Registered 6/24/15
KAYSPIRIS	South Africa Application No. 2018/12687	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date); Registered 7/29/22
Lungs Design (New) 	South Africa Registration No. 2018/14179	Class 5	Filed 5/23/18; Registered 10/10/19
 Lungs Design	South Africa Registration No. 2015/11432	Class 5	Filed 5/4/15 (based on US App. No. 86444498); Registered 7/7/17
RIKACIA	South Africa Registration No. 2014/00183	Class 5	Filed 1/6/14 (claiming 6/28/13 priority date); Registered 8/27/15
SOLIKAYCE	South Africa Registration No. 2018/12689	Class 5	Filed 5/8/18 (claiming 11/10/17 priority date) Registered 7/28/22
VONCERA	South Africa Registration No. 2012/10963	Class 5	Filed 4/26/12; Registered 1/6/14
ARIKACE	South Korea (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 5/6/08
ARIKAYCE	South Korea Registration No. 40-1475869	Class 5	Filed 7/16/18; Registered 5/3/19
ARIKAYCE	South Korea (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13 (claiming 6/28/13 priority date); Statement of Grant of Protection issued 7/9/15
ENSODEPPI	South Korea (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	South Korea (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Registered 4/28/14 (based on U.S. Appl. No. 86103118);

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
			Statement of Grant of Protection issued 3/19/15
INSMED	South Korea (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22; (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	South Korea (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Filed 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 8/6/19
PULMOVANCE	South Korea (via Madrid Protocol) IR Reg. No. 1405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 9/25/19
YUUIPTA	South Korea (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	Switzerland (via Madrid Protocol) IR Reg. No. 919298	Class 5	Registered 3/9/07; Statement of Grant of Protection issued 6/18/13
ARIKAYCE	Switzerland Registration No. 719035	Class 5	Filed 7/17/18; Registered 7/19/18
ARIKAYCE	Switzerland (via Madrid Protocol) IR Reg. No. 1193205	Class 5	Registered 12/27/13; (claiming 6/28/13 priority date)
ENSOPEPPI	Switzerland (via Madrid Protocol) IR Application No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
INSMED	Switzerland Registration No 736003	Class 5	Registered 9/17/19
INSMED	Switzerland (via Madrid Protocol) IR Reg. No. 1205306	Class 5	Filed 4/28/14 (based on U.S. Appl. No. 86103118); Statement of Grant of Protection issued 9/6/19
INSMED	Switzerland (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
Lungs Design (New) 	Switzerland (via Madrid Protocol) IR Reg. No. 1418071	Class 5	Registered 5/23/18 (claiming 12/15/17 priority date); Statement of Grant of Protection issued 8/15/19
PULMOVANCE	Switzerland (via Madrid Protocol) IR Reg. No. 1405839	Class 5, 10, 44	Registered 2/28/18; Statement of Grant of Protection issued 3/22/19
YUUIPTA	Switzerland (via Madrid Protocol) IR Application No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app)
ARIKACE	United Kingdom Registration No. UK00800919298	Class 5	Registered 3/9/07
ARIKAYCE	United Kingdom Registration No. UK00003430483	Class 5	Filed 9/22/19; Registered 12/13/19

MARK	COUNTRY APPLICATION/ REGISTRATION NO.	CLASS	Filing Date Registration Date
ARIKAYCE	United Kingdom Registration No. UK00918178392	Class 5	Registered 1/8/20
ARIKAYCE	United Kingdom Registration No. UK00801193205	Class 5	Registered 12/7/13
	United Kingdom Registration No. UK00917898230	Class 35, 41	Registered 9/19/18
ENSODEPPI	United Kingdom (via Madrid Protocol) IR Registration No. 1623021	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app) Statement of Grant of Protection issued 2/9/22
INSMED	United Kingdom Registration No. UK00003369709	Class 5	Filed 1/24/19; Registered 4/12/19
INSMED	United Kingdom Registration No. UK00918014385	Class 5	Registered 4/24/19
INSMED	United Kingdom Registration No. UK00801205306	Class 5	Registered 4/28/14
INSMED	United Kingdom (via Madrid Protocol) App. No. 1681941	Class 5	Filed 7/21/22 (claiming priority of 1/27/22 and 2/1/22 U.S. applications)
KAYSPIRIS	United Kingdom Registration No. UK00801412075	Class 5	Registered 5/9/18
Lungs Design (New) 	United Kingdom Registration No. UK00801418071	Class 5	Registered 5/23/18
	United Kingdom Registration No. UK00917898231	Class 35, 41	Registered 5/9/18
NTM	United Kingdom Registration No. UK00915538267	Class 35, 41	Registered 11/10/16
NTM ACTION & Design 	United Kingdom Registration No. UK00003541521	Class 41	Filed 10/7/20; Claim of priority from US app 88/876,082; Registered 2/5/21
	United Kingdom Application No. UK00003349402	Class 35, 41	Filed 10/30/18 (claiming U.S. priority date); Registered 1/18/19
	United Kingdom Registration No. UK00917975780	Class 35, 41	Registered 10/30/18
	United Kingdom Registration No. UK00917898232	Class 35, 41	Registered 5/9/18

<b>MARK</b>	<b>COUNTRY APPLICATION/ REGISTRATION NO.</b>	<b>CLASS</b>	<b>Filing Date Registration Date</b>
PULMOVANCE	United Kingdom Registration No. UK00003430485	Class 5, 10, 44	Filed 9/22/19; Registered 12/13/19
PULMOVANCE	United Kingdom Registration No. UK00801405839	Class 5, 10, 44	Filed 2/28/18
YUVIPTA	United Kingdom (via Madrid Protocol) IR Registration No. 1636763	Class 5	Filed 8/18/21 (includes 2/23/21 claim of priority of US app); Statement of Grant of Protection issued 4/3/22